Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.68 |
| ▸ | GABRA1 | P14867 | 5/20 | 0.58 |
| ▸ | GABRB2 | P47870 | 4/20 | 0.58 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.58 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.58 |
| ▸ | HPGD | P15428 | 2/20 | 0.58 |
| ▸ | FAAH | O00519 | 1/20 | 0.58 |
| ▸ | CA1 | P00915 | 1/20 | 0.58 |
| ▸ | CA2 | P00918 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.58 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.58 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.58 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.58 |
| ▸ | HTR2C | P28335 | 1/20 | 0.58 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.58 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.58 |
| ▸ | HTR2B | P41595 | 1/20 | 0.58 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL561299 | 1.00 | TSHR (0.68) | TSHRGABRA1GABRB2GABRG2GABRB3 | |
| SCHEMBL560346 | 1.00 | TSHR (0.68) | TSHRGABRA1GABRB2GABRG2GABRB3 | |
| SCHEMBL202738 | 1.00 | TSHR (0.68) | TSHRGABRA1GABRB2GABRG2GABRB3 | |
| Hydrochloric Acid SCHEMBL7076051 | 0.98 | TSHR (0.65) | TSHRGABRA1GABRB2GABRG2GABRB3 | |
| Hydrochloric Acid SCHEMBL6039756 | 0.96 | TSHR (0.63) | TSHRGABRA1GABRB2GABRG2GABRB3 | |
| SCHEMBL248963 | 0.94 | GABRA1 (0.71) | TSHRGABRA1GABRB2GABRG2GABRB3 | |
| SCHEMBL249795 | 0.94 | GABRA1 (0.71) | TSHRGABRA1GABRB2GABRG2GABRB3 | |
| SCHEMBL249198 | 0.94 | GABRA1 (0.71) | TSHRGABRA1GABRB2GABRG2GABRB3 | |
| SCHEMBL2784586 | 0.89 | TSHR (0.73) | TSHRGABRA1GABRB2GABRG2GABRB3 | |
| SCHEMBL771406 | 0.87 | TSHR (0.59) | TSHRGABRA1GABRB2GABRG2GABRB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110256269-A | A kind of water solubility Propofol analog derivative and application thereof | 江苏恩华络康药物研发有限公司 | 2019-09-20 | — | — | CN | disclosed |
| US-20160089341-A1 | METHODS FOR TREATING AND PREVENTING STATUS EPILEPTICUS AND ORGANOPHOSPHATE POISONING | UNIVERSITY OF IOWA RESEARCH FOUNDATION | 2016-03-31 | — | — | US | disclosed |
| EP-2810927-A1 | Therapeutic compounds | Sowood Healthcare LLC (US) | 2014-12-10 | — | — | EP | disclosed |
| US-8871815-B2 | Therapeutic compounds | SIGNATURE THERAPEUTICS, INC. (US) | 2014-10-28 | — | — | US | disclosed |
| US-20140206773-A1 | Therapeutic Compounds | SIGNATURE THERAPEUTICS, INC. (US) | 2014-07-24 | — | — | US | disclosed |
| EP-2301908-B1 | (-)-stereoisomer of 2,6-di-sec-butylphenol and analogs thereof for promoting antiemetic effect, treatment of nausea and vomiting and treatment of migraine | SIGNATURE THERAPEUTICS INC (US) | 2014-06-25 | — | — | EP | disclosed |
| US-8575400-B2 | Therapeutic compounds | SIGNATURE THERAPEUTICS, INC. (US) | 2013-11-05 | — | — | US | disclosed |
| US-20130059919-A1 | Therapeutic Compounds | SOWOOD HEALTHCARE LLC | 2013-03-07 | — | — | US | disclosed |
| US-8242315-B2 | Stereoisomers propofol therapeutic compounds | Singature Therapeutics, Inc. (US) | 2012-08-14 | — | — | US | disclosed |
| US-20120035271-A1 | Stereoisomers Propofol Therapeutic Compounds | SOWOOD HEALTHCARE LLC | 2012-02-09 | — | — | US | disclosed |
| US-8071818-B2 | Therapeutic compounds | PHARMACOFORE, INC. (US) | 2011-12-06 | — | — | US | disclosed |
| EP-2301908-A1 | (-)-stereoisomer of 2,6-di-sec-butylphenol and analogs thereof for promoting antiemetic effect and treatment of nausea and vomiting | Pharmacofore, Inc. (US) | 2011-03-30 | — | — | EP | disclosed |
| EP-2292577-A1 | (+)-stereoisomer of 2,6-di-sec-butylphenol and analogs thereof | Pharmacofore, Inc. (US) | 2011-03-09 | — | — | EP | disclosed |
| US-20100292346-A1 | Stereoisomers Propofol Therapeutic Compounds | SOWOOD HEALTHCARE LLC | 2010-11-18 | — | — | US | disclosed |
| EP-2146946-B1 | (-)- stereoisomer of 2,6-di-sec-butylphenol and analogs thereof | PHARMACOFORE INC (US) | 2010-11-10 | — | — | EP | disclosed |
| EP-2146946-A2 | STEREOISOMERIC PROPOFOL THERAPEUTIC COMPOUNDS | Pharmacofore, Inc. (US) | 2010-01-27 | — | — | EP | disclosed |
| WO-2008141097-A2 | STEREOISOMERS PROPOFOL THERAPEUTIC COMPOUNDS | PHARMACOFORE, INC. (US) | 2008-11-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130059919-A1 | Therapeutic Compounds | SCN1B, ABCB11, SLC10A1 | TSHR 1937/4885GABRA1 253/4885GABRB2 254/4885 |
| US-20100292346-A1 | Stereoisomers Propofol Therapeutic Compounds | GABRP, OPRM1, OPRD1 | TSHR 1929/4885GABRA1 19/4885GABRB2 24/4885 |
| US-20140206773-A1 | Therapeutic Compounds | OPRM1, OGFR, OPRD1 | TSHR 1516/4885GABRA1 122/4885GABRB2 159/4885 |
| US-20120035271-A1 | Stereoisomers Propofol Therapeutic Compounds | GABRP, OPRM1, OPRD1 | TSHR 1929/4885GABRA1 19/4885GABRB2 24/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.